PCV 24
Alternative Names: 24-valent Pneumococcal Polysaccharide Conjugate Vaccine; PCV-24Latest Information Update: 18 Sep 2024
At a glance
- Originator Sinovac Biotech
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pneumococcal infections
Most Recent Events
- 20 Aug 2024 Sinovac Biotech plans a phase I trial for Pneumococcal infections (Prevention, In Children, In adolescents) in August 2024 (IM, Injection) (NCT06550830)
- 25 Jun 2024 Preclinical trials in Pneumococcal infections (Prevention) in China (IM)
- 20 Jun 2024 Sinovac Life Sciences plans a phase I trial for Pneumococcal infections (Prevention) in China (IM, Injection) (NCT06474377)